Li Yanyan, Ma Xuelei, Zhang Jing, Liu Xiaoxiao, Liu Lei
Center Cancer, State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu - PR China.
Int J Biol Markers. 2014 Sep 30;29(3):e279-87. doi: 10.5301/jbm.5000087.
The identification of microvessel density (MVD) in patients suffering from different types of cancer has become a hot point as an emerging and promising biomarker. The aim of the present study is to clarify the prognostic relevance of MVD in hepatocellular carcinoma (HCC).
Relevant articles were screened in PubMed and EMBASE databases. Patients' clinical characteristics, overall survival (OS), disease/recurrence-free survival (DFS/RFS), and MVD levels were extracted for further analysis. The statistical analysis derived from the Kaplan-Meier survival curves was calculated indirectly with the methods developed by Parmar, Williamson, and Tierney. Multivariate Cox hazard regression analysis was used directly in Stata 11.0. The pooled hazard ratio (HR) and 95% confidence interval (CI) were calculated to evaluate the prognostic role of MVD in HCC.
Our online literature search identified 12 articles including a total of 1,138 HCC patients. Meta-analysis of all the included studies considering survival outcomes showed a positive correlation between poor prognosis and higher-MVD levels. The pooled HRs (and 95% CIs) for OS and DFS/RFS were respectively 2.08 [1.77-2.45] and 2.64 [2.12-3.29]. Subgroup analyses considering tumor stage (I-II/III-IV), tumor size (<5 cm/≥ 5 cm), differentiation (well/poor), or cirrhosis status (≥ 20%/<20%) were also conducted, and all the above analyses supported the prognostic role of MVD in HCC.
Our meta-analysis showed that the available evidence supports the proposition that MVD has a good predictive role in HCC, especially when the patients have late stage, large size, or poorly differentiated tumors.
在不同类型癌症患者中,微血管密度(MVD)作为一种新兴且有前景的生物标志物已成为研究热点。本研究旨在阐明MVD在肝细胞癌(HCC)中的预后相关性。
在PubMed和EMBASE数据库中筛选相关文章。提取患者的临床特征、总生存期(OS)、无病/无复发生存期(DFS/RFS)以及MVD水平进行进一步分析。采用Parmar、Williamson和Tierney开发的方法间接计算来自Kaplan-Meier生存曲线的统计分析结果。直接在Stata 11.0中进行多变量Cox风险回归分析。计算合并风险比(HR)和95%置信区间(CI)以评估MVD在HCC中的预后作用。
我们的在线文献检索确定了12篇文章,共纳入1138例HCC患者。对所有纳入研究的生存结局进行荟萃分析,结果显示预后不良与较高的MVD水平之间存在正相关。OS和DFS/RFS的合并HR(及95%CI)分别为2.08 [1.77 - 2.45]和2.64 [2.12 - 3.29]。还进行了考虑肿瘤分期(I-II/III-IV)、肿瘤大小(<5 cm/≥5 cm)、分化程度(高/低)或肝硬化状态(≥20%/<20%)的亚组分析,上述所有分析均支持MVD在HCC中的预后作用。
我们的荟萃分析表明,现有证据支持MVD在HCC中具有良好预测作用这一观点,尤其是在患者患有晚期、大尺寸或低分化肿瘤时。